TEL AVIV, Israel, Jan. 5, 2021 /PRNewswire/ -- Therapix Biosciences Ltd. (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced it has entered a non-binding letter of intent with Cyntar Ventures Inc., an innovative company dedicated to the development and commercialization of advanced products and therapies in the psychoactive pharmaceutical sphere.